Clinical Trial

Combination of Vebreltinib and Osimertinib in Patients with EGFR 21 L858R Mutation Advanced NSCLC

Name: Combination of Vebreltinib and Osimertinib in Patients with EGFR 21 L858R Mutation Advanced NSCLC — clinical trial record (NCT06827145)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Active, Not Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

This is a Prospective, open label, single arm study to evaluate the efficacy and safety of Vebreltinib combined with Osimertinib in the treatment of locally advanced or metastatic non-small cell lung cancer with EGFR 21 L858R mutation

Trial Details

NCT Number	NCT06827145
Lead Sponsor	National Cancer Center, China Collaborators: Avistone Biotechnology Co., Ltd.
Conditions	Non-Small-Cell Lung Cancer
Enrollment	30 participants
Start Date	2024-10-14
Primary Completion	2026-09 (estimated)
Study Completion	2028-09 (estimated)
Updated on ClinicalTrials.gov	2025-02-14